Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200 Day Moving Average – Here’s Why

Posted by Stanley Muller on Aug 26th, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $7.66 and traded as low as $1.83. Karyopharm Therapeutics shares last traded at $1.86, with a volume of 840,490 shares.

Analyst Upgrades and Downgrades

KPTI has been the topic of several recent research reports. Wall Street Zen lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Royal Bank Of Canada reiterated an “outperform” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. Piper Sandler cut their price objective on Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Weiss Ratings upgraded shares of Karyopharm Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Robert W. Baird cut Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Get Our Latest Analysis on Karyopharm Therapeutics

Karyopharm Therapeutics Stock Up 3.4%

The stock’s 50-day simple moving average is $6.46 and its 200 day simple moving average is $7.63. The company has a market cap of $45.02 million, a price-to-earnings ratio of -0.15 and a beta of 0.89.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The firm had revenue of $33.43 million for the quarter, compared to analyst estimates of $32.19 million. On average, sell-side analysts expect that Karyopharm Therapeutics Inc. will post -4.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $45,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $56,000. Hsbc Holdings PLC purchased a new stake in Karyopharm Therapeutics during the 1st quarter worth approximately $66,000. Corient Private Wealth LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $74,000. Finally, Tudor Investment Corp ET AL purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at approximately $95,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

(Get Free Report)

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.